On 5 June 2025, the Annual General Meeting of Arco Vara AS adopted the decision to issue a targeted share offering to specific investors in order to increase the company’s share capital.Arco Vara AS announces that the targeted share issue approved by the shareholders has been successfully completed as of 11 June 2025 – the management board has adopted a resolution to shorten the subscription period due to early subscription of issued shares. In accordance with the adopted decision of the general meeting: Th ...

PRESS RELEASE In addition to patent protection, AB8939 is also eligible for regulatory data protection in Canada, preventing generic competition for a period of 8 years following initial approval. AB8939 has also received orphan drug designation for AML from both the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). This orphan drug designation provides 10 and 7 years of market exclusivity in Europe and the United States, respectively, after product approval. A separate secondar ...

Utrecht, 12 June 2025 Aalberts announces the successful signing and closing of Note Purchase Agreements for its inaugural debt issuance in the US Private Placement (USPP) market, securing a total equivalent amount of approximately USD 600 million. The transaction comprises approximately USD 500 million and EUR 100 million in Senior Notes, with maturities ranging from 5 to 12 years. Funding has been completed early June. This landmark issuance earmarks a significant milestone in the further optimisation of A ...

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12 BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Bruss ...

SIKA IS UNLOCKING SMART AND DURABLE SOLUTIONS FOR DATA CENTER CONSTRUCTIONToday in Dallas, United States, Sika outlines strategic initiatives and high-performance solutions that will drive the future of data center construction. With over 1,000 data centers built using Sika solutions and a strong pipeline of new projects, Sika has become the trusted partner of technology leaders shaping digital infrastructure worldwide. Global investments in data centers are projected to exceed CHF 400 billion by 20281, dri ...

May was a stable month for Bigbank – both the loan and deposit portfolios grew at a steady pace, and profitability remained at a solid level. The loan portfolio increased by a total of 43 million euros in May. The largest contributions came from business loans and home loans, which grew by 22 million and 15 million euros, respectively. The consumer loan portfolio grew by 6 million euros. The deposit portfolio grew by a total of 26 million euros in May. In a declining interest rate environment, the savings d ...

TORONTO, June 12, 2025 (GLOBE NEWSWIRE) -- Critical One Energy Inc. (formerly Madison Metals Inc.) (“Critical One” or the “Company”) (CSE: CRTL) (OTCQB: MMTLF) (FSE: 4EF0) is pleased to announce that Dark Star Minerals Inc. (“Dark Star”) (CSE: BATT) (FSE: P0W), a well-managed, uranium-focused, publicly-listed company, has entered into an acquisition agreement with Critical One to acquire 100% of its interests in the Khan and Cobra Uranium Projects, located in Namibia’s highly prospective Erongo uranium prov ...

MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") announces the filing of a technical report (the "Technical Report") prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101") in respect of the feasibility study ("2025 FS") for its permitted, 100%-owned Cariboo Gold Project (the "Cariboo Gold Project"), located in central British Columbia, Canada. The Technical Report, ...

Core Insights - Mustang Energy Corp. has initiated an Aerial Electromagnetic Survey (Xcite™ TDEM) over the Spur Project, which is located in a region known for uranium and rare earth elements [1][2] - The survey will cover approximately 10,000 hectares of the claim package that has not been previously surveyed using modern electromagnetic techniques [2] - The Spur Project consists of ten claims covering a total area of 23,680 hectares, situated just south of the Athabasca Basin, a globally recognized area for high-grade uranium deposits [4][6] Company Overview - Mustang Energy Corp. focuses on acquiring and developing high-potential uranium and critical mineral assets, holding a total of 92,211 hectares around the Athabasca Basin [9] - The company has several projects, including the Ford Lake project (7,743 hectares), Cigar Lake East and Roughrider South projects (3,442 hectares), and the Spur Project (23,680 hectares) [9] Survey Technology - The Xcite™ TDEM system is a new generation helicopter-borne time-domain electromagnetic system developed by New Resolution Geophysics, exclusively provided by Axiom Exploration Group in North America [3] - This technology features a patented inflatable transmitter loop with a diameter of approximately 20 meters, suspended about 30 meters below the helicopter, allowing for improved signal clarity and detection of subsurface features [3] Geological Context - The Spur Project's geological setting includes Proterozoic basement rocks and uraniferous pegmatites, indicating potential for uranium, thorium, and rare earth element exploration [4][6] - Adjacent properties have shown high-grade surface grab samples, including up to 8.0% U₃O₈ and 1.93% U, suggesting a promising geological environment for mineralization [6]

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure with reduced ejection fraction (HFrEF) and inflammation, and label extension for Ryoncil® (remestemcel-L-rknd) in adu ...